Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ESKETINTRD1010 | Other Identifier | Janssen Research & Development, LLC | |
| 2015-002654-13 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to evaluate the induction potential of repeated administration of intranasal esketamine on cytochrome P450 (CYP) 3A4 and CYP2B6 activity in healthy participants using orally administered midazolam and bupropion as probes, respectively and to evaluate the pharmacokinetics of esketamine after a single dose and repeated administration.
This is a parallel group, single-center, repeat-dose, fixed-sequence, open-label (all people know the identity of the intervention), study. The effects of repeated administration of intranasal esketamine on the pharmacokinetics of midazolam and bupropion will be evaluated in Cohort 1 and Cohort 2, respectively. Participants in Cohort 1 will receive a single oral dose of midazolam in the morning of Day 1 and Day 17. Participants in Cohort 2 will receive a single oral dose of bupropion in the morning of Day 1 and Day 19. In Cohort 1 and 2 participants will self-administer 5 doses of intranasal esketamine over a 15-day period. The duration of study, from the Screening Phase through Follow-up, is up to 51 days and 54 days for Cohort 1 and Cohort 2, respectively. Blood samples for participants in Cohort 1 will be collected for up to 24 hours after dosing on Days 1 and 17 (midazolam) and for up to 24 hours on Days 2 and 16 (esketamine); For participants in Cohort 2, blood and urine samples for assessment of bupropion pharmacokinetics will be collected for up to 72 hours after dosing on Day 1 and Day 19. Participants' safety will be monitored throughout the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 | Experimental | Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg). |
|
| Cohort 2 | Experimental | Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Midazolam | Drug | Single oral dose of midazolam 6 mg Day 1 and Day 17. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | The Cmax is the maximum plasma concentration. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Time to reach maximum concentration (tmax) | Time to reach the maximum observed plasma concentration. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) | The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last]) | The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Terminal Half-Life(t[1/2]) | Terminal half-life (t[(1/2]) is defined as 0.693/Lambda(z). | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Area Under the Plasma Concentration-Time Curve From Time Zero to 12 hours (AUC [0-12]) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | An AE was any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Merksem | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33128208 | Derived | Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, Perez-Ruixo JJ. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin Pharmacokinet. 2021 Apr;60(4):501-516. doi: 10.1007/s40262-020-00953-4. Epub 2020 Oct 31. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Esketamine |
| Drug |
Intranasal esketamine will be self-administered 5 times during 15 days. |
|
|
| Bupropion | Drug | Single oral dose of bupropion 150 mg on Day 1 and 19. |
|
The AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant. |
| up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Cmax metabolite to parent ratio (MPR Cmax) | Cmax metabolite to parent ratio, and corrected for molecular weight if necessary. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| AUC(last) metabolite to parent ratio (MPR AUC[last]) | AUC(last) metabolite to parent ratio, and corrected for molecular weight if necessary. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| AUC (infinity) metabolite to parent ratio (MPR AUC [infinity]) | AUC (infinity) metabolite to parent ratio, and corrected for molecular weight if necessary. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Amount of Drug excreted in Urine (Ae) | Total amount excreted into the urine, calculated as the sum of all Ae(t1-t2) intervals. | up to Day 17 for Cohort 1; up to Day 19 for Cohort 2 |
| Percentage of Drug dose excreted into urine | Total amount excreted into the urine, expressed as a percentage of the administered dose, calculated as (Ae/dose)*100, and corrected for molecular weight if necessary. | up to Day 19 for Cohort 2 |
| Renal clearance | Renal clearance calculated as Ae/AUC (infinity). | up to Day 19 for Cohort 2 |
| Formation Clearance | Formation clearance of drug, calculated as Ae of hydroxybupropion/AUC(infinity) of bupropion, and corrected for molecular weight if necessary. | up to Day 19 for Cohort 2 |
| Ae metabolite to parent ratio (MPR Ae) | Ae metabolite to parent ratio, and corrected for molecular weight if necessary. | up to Day 19 for Cohort 2 |
| Baseline up to Day 51 for Cohort 1; Baseline up to Day 54 Cohort 2 |
| ID | Term |
|---|---|
| D008874 | Midazolam |
| C000629870 | Esketamine |
| D016642 | Bupropion |
| ID | Term |
|---|---|
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D011427 | Propiophenones |
| D007659 | Ketones |
| D009930 | Organic Chemicals |
Not provided
Not provided